

6ER – 018 ATC 5: Research performed on artificial model

USE OF ELTROMBOPAG IN ROUTINE CLINICAL PRACTICE

CL. Fernández Laguna, L. Macía Rivas, V. García Jiménez, I. Maray Mateos, C. Álvarez Asteinza, S. Fernández Lastras, I. De la Fuente Villaverde, M. Eiroa Osorio, L. Oyague López, A. Lozano Blázquez. Hospital Universitario Central de Asturias

OBJECTIVES

- 1. To evaluate the use of eltrombopag in routine clinical practice and its compliance with the Summaries of product characteristics (SmPC)
- 2. To measure the efficacy according to platelet count response and the need for other concomitant treatments

MATERIALS AND METHODS

Observational, retrospective and descriptive study of adult patients who received treatment with eltrombopag from 06/2020 to 10/2021


The following variables were collected from the electronic medical record: **Demographic data** □ Therapeutic indication

Efficacy was established according to platelet counts three and six months after initiation of treatment, aiming for values between 50.000-150.000 platelets/ μ L (pl/ μ L)

- □ Initial dose
- Platelet count

Concomitant treatments related to hemostasis

N= 35 (54% women) Median age: 68 years (26-95) RESULTS



Primary immune thrombocytopenia (26)


Severe aplastic anemia (1)


- Recovery of normal platelet counts in patients with oncohematological diseases (4)
- Patients with hereditary bleeding disorders (2)
- Secondary thrombopenias (2)

PLATELET COUNT

Initial mean platelet count 41.710 pl/ μ L

making the difference in medication





CONCLUSIONS

- 1. Eltrombopag was used on-label in most patients and a high percentage started with the recommended dose according to the SmPC.
- 2. The evolution of the platelet count shows the efficacy of eltrombopag, with a minority of patients having platelet counts below 50.000 platelets/µL and only eleven patients requiring adjuvant treatment